The Neoliberal Regulatory State, Industry Interests, and the Ideological Penetration of Scientific Knowledge
Authors:
- 24 November 2011
- journal article
- Published by SAGE Publications in Science, Technology, & Human Values
- Vol. 37 (5) , 443-477
Abstract
It is argued that neoliberal political ideology has redefined the regulatory state to have greater convergence of interests and goals with the pharmaceutical industry than previously, particularly regarding acceleration and cost reduction of drug development and regulatory review. Consequently, the pharmaceutical industry has been permitted to set the agenda about how shorter term and cheaper alternative carcinogenicity testing systems are investigated for validity. The authors contend that, with the tacit approval of the neoliberal regulatory state, the commercial interests of the pharmaceutical industry framed the process and interpretation of validating these new test systems, thereby influencing what counts as knowledge about the carcinogenic status of new pharmaceuticals. While such alternative tests were occasioned by “molecularization,” the framing of their validation was not determined by technoscientific logic or a lack of standards of validation, but by the sociopolitical goals of the controlling institutions. Indeed, a different validation process could have been conducted had the priority been to develop carcinogenicity testing in the interests of public-health protection. While the resulting validation indicated that the short-term alternative tests posed small risks to the commercial interests of pharmaceutical firms, they provided little reassurance that patients would not be exposed to greater risks than before from undetected carcinogens.Keywords
This publication has 48 references indexed in Scilit:
- Imagination and technoscientific innovations: Governance of transgenic cows in New ZealandSocial Studies of Science, 2010
- International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use2010
- Deficits, Expectations and Paradigms in British and American Drug Safety AssessmentsScience, Technology, & Human Values, 2007
- Interpellative Sociology of Pharmaceuticals: Problems and Challenges for Innovation and Regulation in the 21st CenturyTechnology Analysis & Strategic Management, 2007
- From Evidence to Theory: Neo-Liberal Corporate Bias as a Framework for Understanding UK Pharmaceuticals Regulation – Response to Alison EdgleySocial Theory & Health, 2007
- Trading risks for markets: The international harmonisation of pharmaceuticals regulationHealth, Risk & Society, 2001
- Regulating the cancer-inducing potential of non-steroidal anti-inflammatory drugs: Some lessons from the 1970s and 1980sSocial Science & Medicine, 1998
- Democracy, Technocracy, and the Secret State of Medicines Control: Expert and Nonexpert PerspectivesScience, Technology, & Human Values, 1997
- Scientific Standards and Institutional Interests: Carcinogenic Risk Assessment of Benoxaprofen in the UK and USSocial Studies of Science, 1993
- Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTPMutation Research/Reviews in Genetic Toxicology, 1991